Orpyx Receives CE Mark Approval for SurroSense Rx™ System

Orpyx Medical Technologies Inc. announces early 2014 for EU status with its SurroSense Rx™ device.

Calgary, AB - November, 2013 - Orpyx Medical Technologies Inc. ("Orpyx") gains CE Mark approval for its flagship device, the SurroSense Rx™ System.  As the requirement for certain medical devices sold in the European Union, this CE Mark approval will enable Orpyx to advance sales into this market as well as conduct clinical trials.  The company anticipates international distribution of the device early 2014.

The SurroSense Rx™ System was developed to address a common complication of diabetes, peripheral neuropathy, which affects upwards of 65% of diabetics over the course of their disease and can result in debilitating complications including blisters, ulcers and amputation in some cases.  The SurroSense Rx™ System includes a sensor-embedded insert that collects pressure data from the foot and transmits the data to a smartwatch.  The user is notified when they have exceeded recommended plantar pressure and are provided with instructions as to how to offload pressure and avoid complications.  The system also tracks data over time through a web-based portal so the user can monitor their progress and improve metrics over time.  The SurroSense Rx™ System is intended to help empower diabetic patients to proactively manage peripheral neuropathy and prevent complications before they begin.

For more information, please contact:

Stephanie Zakala
Marketing & Communications Associate, Orpyx Medical Technologies Inc.
O (403) 460-0216
stephanie.zakala@orpyx.com

About Orpyx Medical Technologies:

Orpyx was created out of a profound desire to address the swiftly-growing global diabetes epidemic and its related complications, notably that of diabetic peripheral neuropathy – loss of feeling and sensory feedback in the feet experienced by an estimated 60-percent of the 350 million diabetics worldwide, that can lead to tissue damage, infection, ulceration and amputation.

Founded by Calgary surgical resident Dr. Breanne Everett, Orpyx is behind two highly innovative plantar sensory replacement systems, the SurroSense Rx™ and the SurroGait Rx™, that use pressure sensor-embedded shoe inserts to determine force exerted over the bottom of the feet, and wirelessly transmit collected information to a back pad or smartwatch worn by the user.  Orpyx products focus on patient empowerment and prevention for better outcomes.




Stephanie Zakala
Stephanie Zakala

Author